State Of Wyoming Catalyst Pharmaceuticals, Inc. Transaction History

State Of Wyoming

$676 Million
Q3 2024

A detailed history of State Of Wyoming transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, State Of Wyoming holds 23,219 shares of CPRX stock, worth $523,820. This represents 0.07% of its overall portfolio holdings.

Number of Shares

23,219

Previous 8,226 182.26%

Holding current value

$523,820

Previous $127,000 262.99%

% of portfolio

0.07%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$15.19 - $21.35 $227,743 - $320,100	14,993 Added 182.26%	23,219 $461,000
Q2 2024 Aug 14, 2024	SELL	$14.68 - $16.92 $33,308 - $38,391	-2,269 Reduced 21.62%	8,226 $127,000
Q1 2024 May 13, 2024	BUY	$13.18 - $17.11 $23,104 - $29,993	1,753 Added 20.05%	10,495 $167,000
Q4 2023 Feb 14, 2024	SELL	$11.78 - $17.29 $10,295 - $15,111	-874 Reduced 9.09%	8,742 $146,000
Q3 2023 Nov 14, 2023	SELL	$11.69 - $15.02 $48,525 - $62,348	-4,151 Reduced 30.15%	9,616 $112,000
Q2 2023 Aug 14, 2023	BUY	$11.5 - $18.08 $48,863 - $76,821	4,249 Added 44.64%	13,767 $185,000
Q1 2023 May 12, 2023	SELL	$14.34 - $21.05 $148,791 - $218,414	-10,376 Reduced 52.16%	9,518 $157,000
Q4 2022 Feb 14, 2023	SELL	$12.25 - $19.5 $91,385 - $145,470	-7,460 Reduced 27.27%	19,894 $370,000
Q3 2022 Nov 14, 2022	BUY	$7.06 - $15.52 $26,538 - $58,339	3,759 Added 15.93%	27,354 $351,000
Q2 2022 Aug 15, 2022	SELL	$6.23 - $8.57 $32,776 - $45,086	-5,261 Reduced 18.23%	23,595 $165,000
Q1 2022 May 13, 2022	SELL	$5.31 - $8.31 $20,586 - $32,217	-3,877 Reduced 11.84%	28,856 $239,000
Q4 2021 Feb 11, 2022	BUY	$5.21 - $7.45 $170,538 - $243,860	32,733 New	32,733 $222,000

Others Institutions Holding CPRX

# of Institutions

331

Shares Held

95.3M

Call Options Held

19.1K

Put Options Held

51.1K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.32B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wyoming with notifications on news.

Account